MOLN Molecular Partners AG - American Depositary Shares
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ 10-K/10-Q Mar 12, 2026MOLN Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
MOLN Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Acerca de Molecular Partners AG - American Depositary Shares Descripción general de la empresa de Wikipedia
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.
History
Researchers at the University of Zürich, Switzerland formed Molecular Partners AG in 2004 while studying monoclonal antibodies. These scientists discovered and developed the DARPin technology and launched the company using this platform.
Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange (ticker MOLN).
Since July 2021, the company is also listed on the Nasdaq in the US under the ticker symbol MOLN.
DARPins
DARPins are genetically engineered antibody mimetic proteins typically exhibiting highly specific and high-affinity target protein binding. They are derived from natural ankyrin repeat proteins. Repeat proteins are among the most common classes of binding proteins in nature, responsible for diverse functions such as cell signaling and receptor binding. DARPins constitute a new class of potent, specific and versatile small-protein therapies, and are used as investigational tools in various therapeutic and diagnostic applications.
The simplest format of a DARPin is the mono-DARPin, consisting of one DARPin domain with specificity for one target. The molecular mass of a mono-DARPin is about 15 to 20 kDa (kilodaltons), depending on the exact design. Several mono-DARPins can be linked (genetically or chemically) to multi-DARPins, which then combine multiple activities in one therapy. This approach enables the design of medicines that can inhibit multiple disease-specific targets and may improve outcomes for patients living with cancer, ophthalmic diseases and other disorders.
Currently, Molecular Partners has two DARPin molecules in clinical development and a broad pipeline of molecules in preclinical development.
Areas of Focus
Molecular Partners is currently focusing its DARPin platform on the fields of oncology, immuno-oncology, ophthalmology, and infectious diseases.
Partnerships/Business Development
Molecular Partners has negotiated three agreements with Allergan to develop therapies for ophthalmology (including abicipar), one in 2011 and two in 2012. In 2011, the company licensed its lead asset back then, abicipar, to Allergan. In 2012, Molecular Partners and Allergan expanded their relationship by signing two separate new agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.
Since the company's inception in 2004, Molecular Partners licensed additional DARPin candidates to other leading international pharmaceutical companies, such as Amgen, Roche or Janssen.
In October 2020, as part of a joint venture to develop therapeutic drugs to combat COVID-19, the Swiss pharmaceutical giant Novartis bought 6% of all shares outstanding in Molecular Partners at 23CHF a share.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | MOLN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E | -2.6promedio 5A ≈-3.1 | ≈-3.1 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | MOLN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| ROA | -47.3%promedio 5A ≈-17.1% | ≈-17.1% | -45.8% | Débil | |
| ROE | -55.5%promedio 5A ≈-22.1% | ≈-22.1% | 9.3% | Débil | |
| ROIC | -72.4%promedio 5A ≈-31.9% | ≈-31.9% | · | · |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | MOLN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Current Ratio (Ratio corriente) | 8.8promedio 5A ≈10.9 | ≈10.9 | 2.0 | Liquidez sólida | |
| Quick Ratio (Ratio Rápido) | 7.7promedio 5A ≈5.2 | ≈5.2 | 1.5 | Liquidez sólida | |
| Interest Coverage (Cobertura de Intereses) | -11.5promedio 5A ≈-312.0 | ≈-312.0 | -55.0 | Liquidez sólida |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Aún no hay datos fundamentales para este ticker.
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | MOLN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue / Employee (Ingresos / Empleado) | ≈$37.1K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | $-0.35 | — | — | |
| 31 de diciembre de 2025 | $-0.23 | $-0.35 | 32.5% | |
| 30 de junio de 2025 | $-0.54 | — | — | |
| 31 de diciembre de 2024 | $-0.30 | — | — | |
| 30 de junio de 2024 | $-0.43 | — | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | · | $5M | $7M | $190M | $10M | $9M | |
| R&D Expense | $40M | $49M | $49M | $51M | $56M | $56M | |
| SG&A Expense | $15M | $18M | $19M | $22M | $17M | $12M | |
| Operating Income | $-58M | $-61M | $-61M | $117M | $-63M | $-58M | |
| Interest Expense | $5M | $38.0K | $5M | $619.0K | $556.0K | $5M | |
| Interest Income | $2M | $7M | $4M | $2M | $191.0K | $367.0K | |
| Pretax Income | $-62M | $-54M | $-62M | $118M | $-64M | $-63M | |
| Income Tax | $2.0K | $2.0K | $0 | $0 | $2.0K | $-11.0K | |
| Net Income | $-62M | $-54M | $-62M | $118M | $-64M | $-63M | |
| EPS (Basic) | $-1.65 | $-1.59 | $-1.89 | $3.63 | $-2.06 | $-2.51 | |
| EPS (Diluted) | $-1.65 | $-1.59 | $-1.89 | $3.54 | $-2.06 | $-2.51 | |
| Shares (Basic) | 37,271,281 | 34,032,544 | 32,770,665 | 32,469,957 | 31,005,171 | 25,000,652 | |
| Shares (Diluted) | 37,271,281 | 34,032,544 | 32,770,665 | 33,265,567 | 31,005,171 | 25,000,652 | |
| EBITDA | $-58M | $-61M | $-61M | $117M | $-63M | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $83M | $64M | $67M | $88M | $72M | $134M | |
| Receivables | $2M | $2M | $2M | $1M | $26M | $3M | |
| Current Assets | $97M | $154M | $192M | $255M | $164M | $178M | |
| PP&E (Net) | · | · | · | $7M | $8M | $9M | |
| Intangibles | $2.0K | $49.0K | $212.0K | $271.0K | $331.0K | $347.0K | |
| Total Assets | $102M | $159M | $198M | $262M | $173M | $188M | |
| Accounts Payable | $2M | $2M | $1M | $2M | $7M | $6M | |
| Current Liabilities | $11M | $11M | $14M | $17M | $47M | $58M | |
| Total Liabilities | $22M | $17M | $22M | $27M | $65M | $80M | |
| Retained Earnings | $-312M | $-246M | $-192M | $-128M | $-251M | $-195M | |
| Stockholders' Equity | $80M | $142M | $176M | $235M | $107M | $107M |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-51M | $-59M | $-59M | $119M | $-91M | $-29M | |
| CapEx | $714.0K | $705.0K | $575.0K | $1M | $933.0K | $1M | |
| Investing Cash Flow | $73M | $40M | $45M | $-101M | $-22M | $-22M | |
| Financing Cash Flow | $-1M | $14M | $-1M | $-2M | $51M | $113M | |
| Free Cash Flow | $-52M | $-60M | $-60M | $117M | $-92M | · | |
| Levered FCF | $-57M | $-60M | $-65M | $117M | $-92M | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1231.7% | -868.3% | 61.5% | -650.2% | · | |
| Net Margin | · | -1087.4% | -880.7% | 62.2% | -653.9% | · | |
| Pretax Margin | · | -1087.3% | -880.7% | 62.2% | -653.9% | · | |
| EBITDA Margin | · | -1231.7% | -868.3% | 61.5% | -650.2% | · | |
| ROA | -47.3% | -30.3% | -26.9% | 54.2% | -35.4% | · | |
| ROE | -55.5% | -34.0% | -30.1% | 68.8% | -59.5% | · | |
| ROIC | -72.4% | -43.2% | -34.6% | 49.6% | -59.1% | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 8.8 | 14.3 | 13.4 | 14.8 | 3.5 | · | |
| Quick Ratio | 7.7 | 6.1 | 4.8 | 5.2 | 2.1 | · | |
| Interest Coverage | -11.5 | -1611.0 | -11.9 | 188.4 | -114.1 | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | 0.9 | 0.1 | · | |
| Receivables Turnover | · | 2.3 | 4.7 | 14.2 | 0.7 | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue / Share | · | $0.15 | $0.21 | $5.70 | $0.31 | · | |
| Cash Flow / Share | $-1.38 | $-1.74 | $-1.80 | $3.56 | $-2.93 | · | |
| EPS (TTM) | $-1.65 | $-1.59 | $-1.89 | $3.54 | $-2.06 | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $5M | $7M | $190M | $10M | · | |
| Net Income TTM | $-62M | $-54M | $-62M | $118M | $-64M | · | |
| P/E | -2.6 | -3.0 | -2.2 | 1.9 | -9.3 | · | |
| Earnings Yield | -37.9% | -33.5% | -45.2% | 54.0% | -10.7% | · |
Aún no tenemos presentaciones de la SEC para este ticker.
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | · | $5M | $7M | $190M | $10M |
| Margen Operativo % | · | -1231.7% | -868.3% | 61.5% | -650.2% |
| Beneficio neto | $-62M | $-54M | $-62M | $118M | $-64M |
| EPS Diluido | $-1.65 | $-1.59 | $-1.89 | $3.54 | $-2.06 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | 8.8 | 14.3 | 13.4 | 14.8 | 3.5 |
| Ratio Rápido | 7.7 | 6.1 | 4.8 | 5.2 | 2.1 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-52M | $-60M | $-60M | $117M | $-92M |
Propietarios institucionales (13F) 5 declarantes · $13.8M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 2 (+2 vs trimestre anterior) | 1 (-1 vs trimestre anterior) | 0 (-1 vs trimestre anterior) | 0 (0 vs trimestre anterior) | +2K |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | $8 597 182 | 2 221 494 | 62,25% | Acciones |
| BVF INC/IL | $5 145 078 | 1 353 968 | 37,26% | Acciones |
| CITADEL ADVISORS LLC | $65 280 | 17 179 | 0,47% | Acciones |
| MORGAN STANLEY | $1 420 | 367 | 0,01% | Acciones |
| UBS Group AG | $1 080 | 279 | 0,01% | Acciones |
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Biotechnology Value Fund, L.P., BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., Mark N. Lampert ×2 presentaciones | 29 de octubre de 2024 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
MOLN Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
Precio objetivo a 12 meses
5 analistas · 2026-10-22Objetivo medio $10.48 +185,7%
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.